- Home
- IIPR vs VRDN Comparison
IIPR vs VRDN Comparison
Compare IIPR & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIPR
- VRDN
- Stock Information
- Founded
- IIPR 2016
- VRDN 2006
- Country
- IIPR United States
- VRDN United States
- Employees
- IIPR N/A
- VRDN N/A
- Industry
- IIPR Real Estate
- VRDN Medical Specialities
- Sector
- IIPR Finance
- VRDN Health Care
- Exchange
- IIPR Nasdaq
- VRDN Nasdaq
- Market Cap
- IIPR 1.5B
- VRDN 1.3B
- IPO Year
- IIPR 2016
- VRDN N/A
- Fundamental
- Price
- IIPR $51.31
- VRDN $17.41
- Analyst Decision
- IIPR Hold
- VRDN Strong Buy
- Analyst Count
- IIPR 8
- VRDN 11
- Target Price
- IIPR $88.75
- VRDN $38.50
- AVG Volume (30 Days)
- IIPR 261.3K
- VRDN 670.9K
- Earning Date
- IIPR 08-06-2025
- VRDN 08-07-2025
- Dividend Yield
- IIPR 14.79%
- VRDN N/A
- EPS Growth
- IIPR N/A
- VRDN N/A
- EPS
- IIPR 5.20
- VRDN N/A
- Revenue
- IIPR $304,785,000.00
- VRDN $302,000.00
- Revenue This Year
- IIPR N/A
- VRDN N/A
- Revenue Next Year
- IIPR $0.94
- VRDN $17,102.33
- P/E Ratio
- IIPR $9.88
- VRDN N/A
- Revenue Growth
- IIPR N/A
- VRDN 4.86
- 52 Week Low
- IIPR $45.44
- VRDN $9.90
- 52 Week High
- IIPR $138.35
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- IIPR 33.60
- VRDN 58.43
- Support Level
- IIPR $52.85
- VRDN $16.65
- Resistance Level
- IIPR $54.86
- VRDN $18.80
- Average True Range (ATR)
- IIPR 1.52
- VRDN 0.81
- MACD
- IIPR -0.22
- VRDN -0.03
- Stochastic Oscillator
- IIPR 13.27
- VRDN 50.97
About IIPR Innovative Industrial Properties Inc.
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).